INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit

Core Viewpoint - ImmunityBio, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its lead product, Anktiva, which is claimed to be a cancer treatment but has not demonstrated long-term efficacy as stated by the company [4][5]. Company Overview - ImmunityBio is a biotechnology company focused on developing next-generation immunotherapies, with Anktiva being its lead biologics product [3]. Allegations - The lawsuit alleges that ImmunityBio made false claims about Anktiva, including that it would allow all NMIBC patients to be cancer-free long-term, which has not been proven [4]. - It is claimed that the assertion of Anktiva being a cancer vaccine is false, and the Executive Chairman overstated its capabilities [4]. - A warning letter from the U.S. FDA indicated that promotional materials misbranded Anktiva, leading to a 21% drop in stock price following the news [5]. Legal Process - Investors who purchased ImmunityBio securities during the class period (January 19, 2026, to March 24, 2026) can seek to be appointed as lead plaintiff in the class action lawsuit [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is representing the investors in this class action and has a strong track record in securities fraud litigation, recovering over $916 million for investors in 2025 alone [7].